16 September 2026 editorial review · Item
Beta-O2 ßAir bioartificial pancreas (oxygen-refueled macrocapsule): review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Preventing and curing evidence review — 16 September 2026
- Disposition: reviewed; no confirmed content change. Current item
lastReviewed: 2026-08-27. - Claim check: BetaAir's four-recipient Phase 1 showed protected cells without immunosuppression, but insufficient insulin output and no clinically effective glucose benefit. Daily oxygen refills and the small study remain limitations.
- Registry NCT02064309: ACTIVE_NOT_RECRUITING; updated 2026-04-28; enrollment 4 (ACTUAL); primary completion 2027-05 (ESTIMATED); results not posted in retrieved record.
- Primary publication/regulatory sources checked or consulted: ajt.14642.